Page 10 - Graphpad Software Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rabies, a fatal disease in humans and other mammals, is caused by the rabies virus (RABV), and it poses a public health threat in many parts of the world. Once symptoms of rabies appear, the mortality is near 100%. There is currently no effective treatment for rabies. In our study, two human-derived RABV-neutralizing antibodies (RVNA), CR57 and CR4098, were cloned into adeno-associated virus (AAV) vectors, and recombinant AAVs expressing RVNA were evaluated for postexposure prophylaxis after intrathecal injection into RABV-infected rats. At 4 days post-infection with a lethal dose of RABV, 60% of the rats that received an intrathecal injection of AAV-CR57 survived, while 100% of the rats inoculated with AAV-EGFP succumbed to rabies. Overall, these results demonstrate that AAV-encoding RVNA can be utilized as a potential human rabies postexposure prophylaxis.

South koreaUnited statesGang caoRota nodariRamos silvaLuminometer promegaFujirebio malvernLuc rabv telucGraphpad software incNational natural science foundation of chinaNancy laboratory for rabiesDrug administrationDifferent administration waysWorld health organizationHuazhong agricultural universityAdministration in animals